Sixty day trial of a new inhalant dosage form of metaproterenol.
A 5% solution of metaproterenol, 10 whiffs (1.5 mg) q.i.d., was administered from a hand bulb nebulizer to 28 asthmatics for 60 days. Spirometry in double-blind, crossover tests against an 0.5% isoproterenol solution on days 0-1 and 59-60 and global evaluations of response showed that metaproterenol was more effective and longer acting. No tolerance to metaproterenol developed. Side-effects were negligible.
D000336:Aerosols; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008297:Male; D008448:Maximal Expiratory Flow Rate; D009921:Metaproterenol / Q000008:administration & dosage* / Q000627:therapeutic use; D012119:Respiration; D013997:Time Factors
D000336:Aerosols; D009921:Metaproterenol; D007545:Isoproterenol